Revon-Rivière G, Banavali S, Heississen L, et al. - Researchers interrogated more than 1,200 physicians in pediatric oncology networks in low- and middle-income countries (LMICs), via an online questionnaire, to know about the experience, practices, opinions, and needs in metronomics (combines frequent administrations of low-dose chemotherapy with drug repurposing, which consists of using already-approved drugs for new medical applications) of physicians working in LMICs. Response from 17% of overall physicians was obtained. The already use of a metronomic regimen was reported by 54.9% of respondents. Celecoxib (44%) followed by propranolol and valproic acid (17%) were most often cited repositioned drugs. The benefits of outpatient use were emphasized (20%) and low toxicity was expected (24%). The absence of scientific evidence or guidelines was emphasized by 47% of responses. They noted that 33% of responses highlighted the availability or affordability of drugs, and 18% the problem of acceptance or compliance. Overall, metronomics represent a potential answer to unmet requirements in pediatric oncology and is already used in LMICs. As far as the availability of drugs is concerned, an opportunity for improvement still exists. Also, there is a need to develop collaborative protocols and research to produce level A evidence.